ProQR Therapeutics N.V.
PRQRProQR Therapeutics NV (NASDAQ: PRQR) is a Dutch biotechnology company based in Leiden, the Netherlands, with a presence in Cambridge, Massachusetts, US. The company was funded in 2012 by chief executive officer (CEO) Daniel A. de Boer. It specializes in the development of RNA therapeutics using its RNA editing platform technology called Axiomer.
Drugs in Pipeline
4
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
PRQR Earnings Report
EPS Est: $-0.14 | FQ end 2026-06
sepofarsen
Leber Congenital Amaurosis 10
QR-1123
Autosomal Dominant Retinitis Pigmentosa
QR-421a
Retinitis Pigmentosa
QR-010
Cystic Fibrosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
sepofarsen | Phase 3 | Leber Congenital Amaurosis 10 | - | - |
QR-1123 | Phase 2 | Autosomal Dominant Retinitis Pigmentosa | - | - |
QR-421a | Phase 2 | Retinitis Pigmentosa | - | - |
QR-010 | Phase 2 | Cystic Fibrosis | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in ProQR Therapeutics N.V.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in ProQR Therapeutics N.V.'s (PRQR) pipeline across Phase 3, Phase 2. Its lead program is sepofarsen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ProQR Therapeutics N.V.'s next FDA catalyst?→
ProQR Therapeutics N.V.'s (PRQR) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track PRQR biotech catalysts?→
Add PRQR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ProQR Therapeutics N.V.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.